The linezolid experience and accurate determination of resistance (LEADER) surveillance program has monitored linezolid activity, spectrum, and resistance since 2004. In 2014, a total of 6,865 Gram-positive pathogens from 60 medical centers from 36 states were submitted. The organism groups evaluated were Staphylococcus aureus (3,106), coagulase-negative staphylococci (CoNS; 797), enterococci (855), Streptococcus pneumoniae (874), viridans group streptococci (359), and betahemolytic streptococci (874). Susceptibility testing was performed by reference broth microdilution at the monitoring laboratory. Linezolid-resistant isolates were confirmed by repeat testing. PCR and sequencing were performed to detect mutations in 23S rRNA, L3, L4, and L22 proteins and acquired genes (cfr and optrA). The MIC 50/90 for Staphylococcus aureus was 1/1 g/ml, with 47.2% of isolates being methicillin-resistant Staphylococcus aureus. Linezolid was active against all Streptococcus pneumoniae strains and beta-hemolytic streptococci with a MIC 50/90 of 1/1 g/ml and against viridans group streptococci with a MIC 50/90 of 0.5/1 g/ml. Among the linezolid-nonsusceptible MRSA strains, one strain harbored cfr only (MIC, 4 g/ml), one harbored G2576T (MIC, 8 g/ml), and one contained cfr and G2576T with L3 changes (MIC, >8 g/ ml). Among CoNS, 0.75% (six isolates) of all strains demonstrated linezolid MIC results of >4 g/ml. Five of these were identified as Staphylococcus epidermidis, four of which contained cfr in addition to the presence of mutations in the ribosomal proteins L3 and L4, alone or in combination with 23S rRNA (G2576T) mutations. Six enterococci (0.7%) were linezolid nonsusceptible (>4 g/ml; five with G2576T mutations, including one with an additional cfr gene, and one strain with optrA only). Linezolid demonstrated excellent activity and a sustained susceptibility rate of 99.78% overall.
T
he LEADER (linezolid experience and accurate determination of resistance) program is a national surveillance program which was initiated in 2004 to track the activity of linezolid, in the context of the activity of other Gram-positive agents, against staphylococci, streptococci, and enterococci (1) . This program has provided information on a yearly basis about linezolid resistance mechanisms, including the identification of emerging mechanisms. Throughout the tenure of LEADER, overall linezolid resistance in Gram-positive bacteria has evolved to include new species and mechanisms; however, the overall linezolid resistance rate has remained modest at Ͻ1% (1) (2) (3) (4) (5) (6) (7) (8) (9) .
Linezolid, an oxazolidinone, exerts its antibacterial activity by inhibiting protein synthesis by binding to the 23S subunit of the 50S ribosome (10) (11) (12) (13) . Resistance development appeared early in clinical use in staphylococci and enterococci through ribosomal mutation in the 23S rRNA at G2576T (14, 15) . Later on, an rRNA methyltransferase occurred which conferred resistance not only to linezolid but also to other antimicrobial agents (16) (17) (18) . This cfr rRNA methyltransferase has the potential to mobilize, and although it has occurred in a broader range of species and with more frequency, it still is not the dominant form of linezolid resistance (5, 6, 8, 9, 19) .
In this study, we report the activity of linezolid against Grampositive bacteria collected during the calendar year 2014. A total of 6,865 Gram-positive pathogens were selected from 60 U.S. medical centers from 36 states for the following groups of organisms: Staphylococcus aureus, coagulase-negative staphylococci (CoNS), enterococci, Streptococcus pneumoniae, ␤-hemolytic streptococci, and viridans group streptococci.
(This work was presented in part in abstract form at the 2015 IDWeek meeting in San Diego, CA.)
MATERIALS AND METHODS
Organism collection. During 2014, a total of 6,865 Gram-positive bacterial pathogens were collected from 60 medical centers in 36 states across all nine U.S. Census Bureau regions. There were 4 to 9 medical centers in each U.S. Census Bureau region, and a total of 495 to 1,100 strains were contributed per region.
Each laboratory followed a protocol to submit consecutive isolates (one per patient episode) determined to be pathogens to the monitoring laboratory. The isolates were primarily from invasive bloodstream infections (BSI), pneumonia (respiratory tract), and acute bacterial skin and skin structure infections (ABSSSI), although isolates from other sites were acceptable. The target organisms requested from each medical center were Staphylococcus aureus (50 isolates), CoNS (15 isolates), enterococci (15 isolates), Streptococcus pneumoniae (10 isolates), and beta-hemolytic streptococci and viridans group or other streptococci (five isolates each; total of 10). The monitoring laboratory (JMI Laboratories, North Liberty, IA) confirmed the bacterial identification received from the participant medical center using biochemical methods or matrix-assisted laser desorption ionization-time of flight (MALDI-TOF; Bruker Daltonics, Bremen, Germany) as appropriate.
Susceptibility testing. Susceptibility tests and the confirmation of linezolid-resistant isolates were performed as described previously (4-6, 8, 9) . Briefly, broth microdilution method tests were performed at the mon-itoring reference laboratory using dry-form panels produced by Thermo Fisher (formerly TREK Diagnostics, Cleveland, OH) applying Clinical and Laboratory Standards Institute (CLSI) methods and published interpretive criteria (20, 21) . Linezolid-resistant isolates were confirmed by repeat reference broth microdilution testing (20) using frozen-form broth microdilution panels and with the linezolid Etest (AB Biodisk; bioMérieux, Hazelwood, MO) and CLSI disk diffusion susceptibility testing methods (21, 22) .
Molecular characterization. Molecular testing was performed as previously described on isolates exhibiting elevated linezolid MIC results (MIC, Ն4 g/ml) to identify recognized target site mutations or genes and potential clonality using pulsed-field gel electrophoresis (PFGE). The PFGE profile pattern nomenclature that we used consisted of three types of information. PFGE type was assigned according to the isolate code (initials represent the organism), site identifier (internal JMI institution number), and a capital letter for the PFGE group; e.g., SA468A was an Staphylococcus aureus isolate from JMI site 468 that was PFGE group A. Staphylococci and enterococci were screened for cfr, optrA, and mutations in the central loop of the domain V region of 23S rRNA as well as L3 and L4 ribosomal proteins (16, (23) (24) (25) (26) . Staphylococcus aureus strains that were resistant to erythromycin but susceptible to clindamycin were screened for inducible clindamycin resistance (21) . Fig. 1 ). This rate has decreased each year in the LEADER program from a high of 58.2% (2007) (Fig. 1) . The MRSA rate varied by region in 2014 from 40.0% (New England and west north central) to 57.0% (east south central) (data not shown).
RESULTS

Activity against
The linezolid MIC 50/90 for Staphylococcus aureus was 1/1 g/ml ( Table 2 ). The MIC 50 and modal MIC for MRSA and MSSA were the same, at 1 g/ml (Table 1 and 2). There were only two Staphylococcus aureus (both MRSA) strains that were resistant to linezolid, and one isolate had a MIC of 4 g/ml (Table 3 ). Both resistant isolates were from Long Beach, CA. One harbored a G2576T ribosomal mutation only, while the other harbored multiple mechanisms, which were G2576T, the cfr methyltransferase, and alterations in L3 (Table 3) . PFGE indicated that these two isolates were not related (SA468A and SA468B) ( Table 3 ). The one MRSA isolate with a MIC of 4 g/ml was from New Orleans, LA, and harbored cfr ( Table 3 ). The overall linezolid resistance rate among Staphylococcus aureus isolates was only 0.10% (including the isolate with the elevated linezolid MIC of 4 g/ml harboring cfr). This rate generally has been stable since 2007 (Table 4 ) (3) (4) (5) (6) (7) (8) (9) .
Activity of linezolid against CoNS. All CoNS were susceptible to vancomycin, tigecycline, and teicoplanin (Table 1) . Linezolid and daptomycin also exhibited a high level of activity against CoNS, with susceptibility ranging from 99.1% (linezolid; methicillin-resistant CoNS) to 100.0% (daptomycin; methicillin-resistant CoNS) ( Table  1) . Linezolid potency was not adversely influenced by oxacillin susceptibility or resistance ( Table 2 ). The MIC 50/90 values were 0.5/0.5 g/ml, respectively, and the overall linezolid susceptibility rate was 99.2% (Table 1 and data not shown).
Susceptibility rates for erythromycin, the fluoroquinolones, clindamycin, tetracycline, and gentamicin were lower for methicillinresistant CoNS than for methicillin-susceptible CoNS (Table 1) . For example, susceptibility to erythromycin was 20.0% for MRCoNS and 64.7% for MSCoNS (Table 1 ). Susceptibility to ciprofloxacin and levofloxacin ranged from 41.8 to 42.2% for MRCoNS and 85.0% for MSCoNS ( Table 1 ). The overall oxacillin-resistant CoNS rate was 57.3% ( Table 1 ). The oxacillin-resistant rates varied by U.S. Census Bureau region (49.4 to 68.5%), with the highest rate detected in the east south central region (data not shown).
Six CoNS isolates demonstrated linezolid MIC results of Ն4 g/ml (Table 3 ). Five were identified as Staphylococcus epidermidis, which originated from three states: Texas (2 isolates), California (2 isolates), and Tennessee (1 isolate). For the Texas isolates, one isolate each displayed the same PFGE patterns (SEPI116D and SEPI116E) as isolates from 2011 (7). All but one linezolid-resistant Staphylococcus epidermidis isolate contained cfr in addition to the presence of mutations in the ribosomal proteins L3 and L4, alone or in combination with 23S rRNA (G2576T) mutations (Table 3). MIC values for these isolates were high, ranging from 64 to Ͼ128 g/ml. The linezolid-resistant CoNS isolate which exhibited the lowest MIC value (4 to 8 g/ml; Staphylococcus hominis from Seattle, WA) displayed a cfr and a ribosomal protein mutation (L3) ( Table 3 ).
Activity of linezolid tested against enterococci. A total of 855 enterococci were tested, of which 68.9% were Enterococcus faecalis and 28.0% E. faecium (Table 1 ). The ampicillin susceptibility rate was 74.9% and the vancomycin resistance (VRE) rate was 21.3% (Table 1) . VRE rates varied by U.S. Census Bureau region, ranging from 8.4% (west north central) to 30.3% (south Atlantic). Ampicillin resistance in the enterococci was due primarily to E. faecium (90.0% resistance; data not shown). No E. faecalis isolates were ampicillin resistant. The VanA resistance phenotype represented 92.6% of the VRE. Linezolid, daptomycin, and tigecycline were the most active agents tested against enterococci, with susceptibility rates of 99.3, 99.8, and 100.0%, respectively (Table 1) .
One E. faecalis and five E. faecium (Ն4 g/ml) isolates exhibited nonsusceptible linezolid MIC results. These strains were found in Alaska (2 isolates), California (1 isolate), Georgia (1 isolate), Virginia (1 isolate), and Vermont (1 isolate) ( Table 3 ). All E. faecium nonsusceptible strains had G2576T mutations, and one isolate also harbored cfr (E. faecium from Atlanta, GA; MIC ranged from 4 to 8 g/ml). The E. faecium isolate from Los Angeles displayed a distinct PFGE profile different from that of a nonsusceptible isolate recovered there during 2013 (9) . One E. faecalis isolate harbored the optrA gene.
Activity of linezolid tested against Streptococcus pneumoniae. Linezolid was active against Streptococcus pneumoniae (MIC 50 and MIC 90 , 1 g/ml; 100.0% susceptible), with only 0.3% of strains at a MIC of 2 g/ml (susceptible breakpoint) (Tables 1  and 2 ). Vancomycin (100.0% susceptible; MIC 90 , 0.5 g/ml), tigecycline (100.0% susceptible; MIC 90 , 0.03 g/ml), and levofloxacin (98.2% susceptible; MIC 90 , 1 g/ml) were highly active against the pneumococci (Table 1) . Penicillin nonsusceptibility (MIC, Ն0.12 g/ml; oral penicillin V breakpoint) occurred at a rate of 41.5%, and erythromycin resistance (MIC, Ն1 g/ml) occurred at 45.9% (Table 1) . Susceptibility rates of the most active ␤-lactams ranged from 88.8% (amoxicillin-clavulanate) to 93.6% (penicillin at Յ2 g/ml; penicillin parenteral [non-meningitis] breakpoint); ceftriaxone susceptibility was 92.8% (Table 1) . Levofloxacin resistance, at 1.5% in 2014 (MIC, Ն8 g/ml), ranged from 0.0% (Pacific region) to 4.5% in New England (data not shown). The east north central region was the only other region with a levofloxacin resistance rate over 2.0% (2.1%).
Activity of linezolid tested against viridans group streptococci, beta-hemolytic streptococci, and other streptococci. The viridans group streptococci were highly susceptible to linezolid, daptomycin, vancomycin, and tigecycline (all strains were 100.0% susceptible) ( Table 1 ). The susceptibility of the viridans group streptococci was reduced for erythromycin (53.6%), tetracycline (62.0%), and penicillin (81.3%) ( Table  1) . Clindamycin susceptibility was at 88.3%, and levofloxacin nonsusceptibility was 7.2% (0.6%; intermediate category; Table 1 ). Linezolid MICs among the viridans group streptococci were predominantly at 0.5 to 1 g/ml (MIC 50/90 , 0.5/1 g/ml), and no isolate exhibited a linezolid MIC at the susceptible breakpoint of 2 g/ml (Table 2) .
A total of 874 beta-hemolytic streptococci, 39.1% of which were Streptococcus pyogenes and 47.7% of which were Streptococcus agalactiae, were tested (Table 1) . High rates of resistance occurred for erythromycin (36.2%), clindamycin (20.5%), and tetracycline (50.9%) ( Table 1 ). Macrolide resistance varied by region, from a low of 29.1% (south Atlantic) to a high of 51.2% (east south central) (data not shown). Linezolid, tigecycline, daptomycin, penicillin, ceftriaxone, and vancomycin inhibited all beta-hemolytic streptococci tested at their susceptible breakpoints (Table 1) . Susceptibility to levofloxacin was 99.4% (Table 1 ). The linezolid MIC range was 0.25 to 1 g/ml, with 47.5% of isolates at 0.5 g/ml and 50.7% at 1 g/ml (Table 2) . No isolates exhibited a linezolid MIC value at or above the breakpoint concentration of 2 g/ml (Table 2) . (3) (4) (5) (6) (7) (8) (9) . In LEADER 2014, three linezolid-resistant MRSA isolates (including one isolate with a MIC at 4 g/ml with a confirmed resistance mechanism, cfr) from two census regions were detected. One MRSA isolate harbored cfr only (MIC, 4 g/ml), one harbored G2576T only (MIC, 8 g/ml), and one contained cfr and G2576T with L3 changes (MIC, Ն8 g/ml). Inducible clindamycin resistance among erythromycin-resistant, clindamycin-susceptible Staphylococcus aureus strains was 21.1% overall but was decreased compared to rates in previous years (3) (4) (5) (6) (7) (8) (9) . Overall clindamycin resistance remained high. Among erythromycin-resistant, clindamycin-susceptible strains, the highest rate of inducible clindamycin resistance (44.4%) was in New England, as was the case in previous years (44.4% in 2013, 47.0% in 2012, and 44.8% in 2011) (7) (8) (9) .
In the 2014 program, nonsusceptibility to linezolid occurred among the enterococci (0.70%; five E. faecium and one E. faecalis strain) and six CoNS (0.75%; five Staphylococcus epidermidis with MIC of Ն8 g/ml and one Staphylococcus hominis with a MIC of 8 g/ml and containing a cfr and L3 mutation). Each of two linezolid-nonsusceptible Staphylococcus epidermidis isolates from Houston displayed the same PFGE patterns as previous isolates from 2011 (SEPI116D and SEPI116E PFGE, respectively) (7).
Overall, there were 15 nonsusceptible isolates, 8 of which (53.3%) harbored a cfr gene. During the previous LEADER program years 2011 through 2013, the percentage of linezolid-nonsusceptible isolates harboring cfr ranged from 13 to 25% (7-9). As cfr confers resistance to multiple classes of antibiotics, its presence limits the potential use of other agents (18, 19, 24) . This increase in the presence of cfr in the linezolid-nonsusceptible isolates is concerning and deserves watching in next year's LEADER surveillance, especially considering the fact that cfr may be transmissible 
